​The European Parliament adopted a resolution on the evaluation of the pandemic in its sitting on the 8th March 2011.

EMA recommends restricting use in persons under 20 years of age Pandemrix to be used only in the absence of seasonal trivalent influenza vaccines, following link to very rare cases of narcolepsy in young people. Overall benefit-risk remains positive.

The study of Wood et al has shown a standard can reduce the inter-laboratory variability of the results and bring coherence to the inter-assay results as well.